Literature DB >> 27112662

The antioxidant protein PARK7 plays an important role in cell resistance to Cisplatin-induced apoptosis in case of clear cell renal cell carcinoma.

Rachana Trivedi1, Gry H Dihazi2, Marwa Eltoweissy2, Durga P Mishra3, Gerhard A Mueller2, Hassan Dihazi4.   

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most malignant tumor in the adult kidney. Many factors are responsible for the development and progression of this tumor. Increased reactive oxygen species accumulation and altered redox status have been observed in cancer cells and this biochemical property of cancer cells can be exploited for therapeutic benefits. In earlier work we identified and characterize Protein DJ-1 (PARK7) as an oxidative stress squevenger in renal cells exposed to oxidative stress. To investigate whether the PARK7 or other oxidative stress proteins play a role in the renal cell carcinoma and its sensitivity or resistance to cytostatic drug treatment, differential proteomics analysis was performed with a cell model for clear cell renal carcinoma (Caki-2 and A498). Caki-2 cells were treated with cisplatin and differentially expressed proteins were investigated. The cisplatin treatment resulted in an increase in reactive oxygen species accumulation and ultimately apoptosis of Caki-2 and A498 cells. In parallel, the apoptotic effect was accompanied by a significant downregulation of antioxidant proteins especially PARK7. Knockdown of PARK7 using siRNA and overexpression using plasmid highlights the role of PARK7 as a key player in renal cell carcinoma response to cisplatin induced apoptosis. Overexpression of PARK7 resulted in significant decrease in apoptosis, whereas knockdown of the protein was accompanied by an increase in apoptosis in Caki-2 and A498 cells treated with cisplatin. These results highlights for the first time the important role of PARK7 in cisplatin induced apoptosis in clear renal cell carcinoma cells.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  6-diamidino-2-phenylindole (PubChem CID: 160166); Apoptosis; CHAPS (PubChem CID: 107670); Caki-2; Cisplatin; Cisplatin (PubChem CID: 441203); DTT (PubChem CID: 446094); H2DCFDA (PubChem CID: 77718); PARK7; PMSF (PubChem CID: 4784); Reactive oxygen species; Renal cell carcinoma; Tris (PubChem CID: 93573); acetonitrile (PubChem CID: 6342); bromophenol blue (PubChem CID: 8272); glycerol (PubChem CID: 753); iodoacetamide (PubChem CID: 3727); l-glutamine (PubChem CID: 5961); paraformaldehyde solution (PubChem CID: 712); penicillin (PubChem CID: 5904); propidium iodide (PubChem CID: 104981); streptomycin (PubChem CID: 19649); trifluoroacetic acid (PubChem CID: 6422); urea (PubChem CID: 1176)

Mesh:

Substances:

Year:  2016        PMID: 27112662     DOI: 10.1016/j.ejphar.2016.04.014

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

1.  DJ-1 Alters Epirubicin-induced Apoptosis via Modulating Epirubicinactivated Autophagy in Human Gastric Cancer Cells.

Authors:  Xue-Kai Pan; Fei Su; Li-Hua Xu; Zhang-Shuo Yang; Dan-Wen Wang; Li-Jie Yang; Fan-Zheng Kong; Wei Xie; Mao-Hui Feng
Journal:  Curr Med Sci       Date:  2018-12-07

2.  Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer.

Authors:  Stephen Shang; Jiekun Yang; Amir A Jazaeri; Alexander James Duval; Turan Tufan; Natasha Lopes Fischer; Mouadh Benamar; Fadila Guessous; Inyoung Lee; Robert M Campbell; Philip J Ebert; Tarek Abbas; Charles N Landen; Analisa Difeo; Peter C Scacheri; Mazhar Adli
Journal:  Cancer Res       Date:  2019-07-29       Impact factor: 12.701

3.  Bis-isatin derivatives: design, synthesis, and biological activity evaluation as potent dimeric DJ-1 inhibitors.

Authors:  Xiao-Bing Chen; Hai-Ying Zhu; Kun Bao; Li Jiang; Hong Zhu; Mei-Dan Ying; Qiao-Jun He; Bo Yang; Rong Sheng; Ji Cao
Journal:  Acta Pharmacol Sin       Date:  2021-01-25       Impact factor: 7.169

Review 4.  Novel Insights into PARK7 (DJ-1), a Potential Anti-Cancer Therapeutic Target, and Implications for Cancer Progression.

Authors:  Wook Jin
Journal:  J Clin Med       Date:  2020-04-26       Impact factor: 4.241

5.  Improved detection of prostate cancer using a magneto-nanosensor assay for serum circulating autoantibodies.

Authors:  Lingyun Xu; Jung-Rok Lee; Shiying Hao; Xuefeng Bruce Ling; James D Brooks; Shan X Wang; Sanjiv Sam Gambhir
Journal:  PLoS One       Date:  2019-08-12       Impact factor: 3.240

6.  Alcohol consumption, tobacco smoking, and subsequent risk of renal cell carcinoma: The JPHC study.

Authors:  Tetsuji Minami; Manami Inoue; Norie Sawada; Taiki Yamaji; Motoki Iwasaki; Shoichiro Tsugane
Journal:  Cancer Sci       Date:  2021-10-19       Impact factor: 6.716

7.  Protective role of DJ-1 in endotoxin-induced acute kidney injury.

Authors:  Joseph Leeds; Yogesh Scindia; Valentina Loi; Ewa Wlazlo; Elizabeth Ghias; Sylvia Cechova; Didier Portilla; Jonathan Ledesma; Sundararaman Swaminathan
Journal:  Am J Physiol Renal Physiol       Date:  2020-07-27

8.  Regulation of Reactive Oxygen Species and the Antioxidant Protein DJ-1 in Mastocytosis.

Authors:  Do-Kyun Kim; Michael A Beaven; Joseph M Kulinski; Avanti Desai; Geethani Bandara; Yun Bai; Calman Prussin; Lawrence B Schwartz; Hirsh Komarow; Dean D Metcalfe; Ana Olivera
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

9.  Network-based analysis of oligodendrogliomas predicts novel cancer gene candidates within the region of the 1p/19q co-deletion.

Authors:  Josef Gladitz; Barbara Klink; Michael Seifert
Journal:  Acta Neuropathol Commun       Date:  2018-06-11       Impact factor: 7.801

10.  Silencing of the chemokine CXC receptor 4 (CXCR4) hampers cancer progression and increases cisplatin (DDP)-sensitivity in clear cell renal cell carcinoma (ccRCC).

Authors:  Wenguang Wang; Zhilu Gan; Qiang Liu; Shenshen Yan; Rexiti Mulati; Yujie Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.